Search

Your search keyword '"Kuwaki, Kenji"' showing total 184 results
Start Over Author "Kuwaki, Kenji" Search Limiters Peer Reviewed
184 results on '"Kuwaki, Kenji"'

1. Association of depression and smoking cessation: outcomes of an 18-year retrospective cohort study.

Author

Kawai, Haruyuki, Kondo, Jun, Kuwaki, Kenji, Hayashibara, Maiko, Nakamura, Aguri, Sato, Naoko, Fujii, Mari, Kato, Mihoko, Ohara, Tomomi, Wakimoto, Naomi, Honiden, Mika, and Takata, Shinji

Subjects
SMOKING cessation, SUCCESS, DRUG addiction, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, SCHIZOPHRENIA, LONGITUDINAL method, KAPLAN-Meier estimator, STATISTICS, MEDICAL records, ACQUISITION of data, CONFIDENCE intervals, MENTAL depression, PROPORTIONAL hazards models
Abstract

Background: Depression is frequently associated with unsuccessful smoking cessation. Objective: In this study, we investigated the impact of depression history on smoking cessation success in a clinical setting. Methods: This retrospective study included 726 patients who visited our smoking cessation clinic between January 1, 2001, and December 31, 2018. Kaplan–Meier analyses and Cox proportional hazards regression models were used to perform univariate and multivariate analyses of smoking cessation success factors. Results: Among the 726 patients, 76 had a history of depression and demonstrated significantly lower 12-week quit rate compared to those without (33.6% vs. 69.6%, p <.001). Multivariate Cox analysis revealed a significant association between abstinence rate and history of depression (hazard ratio 2.251, 95% CI 1.505–3.315, p <.001), history of schizophrenia (hazard ratio 2.716, 95% CI 1.427–4.840, p =.003), and Fagerström Nicotine Dependence Test scores (hazard ratio 1.519, 95% CI 1.053–2.197, p =.025). Conclusions: Our findings suggested that a history of depression is a significant prognostic factor for smoking cessation, underscoring the need for targeted interventions for patients with a history of depression. The findings of this study are subject to potential selection bias due to recruitment from a single hospital, which may limit the generalizability of our results. This study highlights the necessity for novel, specialized smoking cessation therapies to support patients with a history of depression in their cessation journey. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

Author

Kikuchi, Tatsuya, Takeuchi, Yasuto, Nouso, Kazuhiro, Kariyama, Kazuya, Kuwaki, Kenji, Toshimori, Junichi, Iwado, Shota, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Tada, Toshifumi, Yasunaka, Tetsuya, Sakata, Masahiro, Sue, Masahiko, Miyake, Nozomi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, and Takaki, Akinobu

Subjects
CONVERSION therapy, CANCER chemotherapy, ATEZOLIZUMAB, BEVACIZUMAB, ABLATION techniques, HEPATOCELLULAR carcinoma
Abstract

Background: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC). Methods: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first‐line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer‐free status were identified. Results: Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p =.03) and tended to have lower Child‐Pugh scores and alpha‐fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1–13]; p =.04). Furthermore, 10 (66.7%) patients achieved cancer‐free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p <.01), and a shorter interval between systemic chemotherapy induction and conversion therapy (131 vs. 404 days; p <.01). In addition, the rate of achieving cancer‐free status by undergoing surgical resection or ablation therapy was significantly higher (p =.03). Conclusion: BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer‐free status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Author

Akimoto, Yutaka, Nouso, Kazuhiro, Kato, Hironari, Miyahara, Koji, Dohi, Chihiro, Morimoto, Yuki, Kinugasa, Hideaki, Tomoda, Takeshi, Yamamoto, Naoki, Tsutsumi, Koichiro, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Okada, Hiroyuki, Amano, Maho, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

9. Surgical Management of Giant Unruptured Left Sinus of Valsalva Aneurysm With Severe Aortic Regurgitation.

Author

Ozawa, Keisuke, Kuwaki, Kenji, Furuya, Hidekazu, Yamaguchi, Masaomi, and Yamamoto, Akiyoshi

Subjects
*SINUS of valsalva, *AORTIC aneurysms, *AORTIC valve insufficiency, *CORONARY arteries
Abstract

Left sinus of Valsalva aneurysms are extremely rare. Concomitant aortic valve regurgitation is a comorbidity in this pathology. This case report summarizes successful surgical treatment with aortic root replacement with a modified Bentall procedure in a 49-year-old female patient who had an unruptured huge left sinus of Valsalva aneurysm with severe aortic valve regurgitation. The intraoperative assessment showed severe adhesion between the left main trunk of the coronary artery and the left sinus of Valsalva aneurysm, and meticulous adhesion detachment was required. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf‐3 expressing adenoviral vector for hepatocellular carcinoma

Author

Sawahara, Hiroaki, Shiraha, Hidenori, Uchida, Daisuke, Kato, Hironari, Kato, Ryo, Oyama, Atsushi, Nagahara, Teruya, Iwamuro, Masaya, Horiguchi, Shigeru, Tsutsumi, Koichiro, Mandai, Mari, Mimura, Tetsushige, Wada, Nozomu, Takeuchi, Yasuto, Kuwaki, Kenji, Onishi, Hideki, Nakamura, Shinichiro, Watanabe, Masami, Sakaguchi, Masakiyo, Takaki, Akinobu, Nouso, Kazuhiro, Yagi, Takahito, Nasu, Yasutomo, Kumon, Hiromi, and Okada, Hiroyuki

Published
2017
Full Text
View/download PDF

15. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion

Author

Onishi, Hideki, Nouso, Kazuhiro, Nakamura, Shinichiro, Katsui, Kuniaki, Wada, Nozomu, Morimoto, Yuki, Miyahara, Koji, Takeuchi, Yasuto, Kuwaki, Kenji, Yasunaka, Tetsuya, Miyake, Yasuhiro, Shiraha, Hidenori, Takaki, Akinobu, Kobayashi, Yoshiyuki, Sakaguchi, Kohsaku, Kanazawa, Susumu, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

17. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis

Author

Yamasaki, Yasushi, Nouso, Kazuhiro, Miyahara, Koji, Wada, Nozomu, Dohi, Chihiro, Morimoto, Yuki, Kinugasa, Hideaki, Takeuchi, Yasuto, Yasunaka, Tetsuya, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwasaki, Yoshiaki, Amano, Maho, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

18. Posterior mitral leaflet augmentation with autologous pericardial patch for the surgical treatment of severe atrial functional mitral regurgitation.

Author

Furuya, Hidekazu, Kuwaki, Kenji, Ozawa, Keisuke, and Yamaguchi, Masaomi

Subjects
*MITRAL valve insufficiency, *MITRAL valve, *ATRIAL fibrillation, *HEART failure, *PERICARDIUM
Abstract

Atrial functional mitral regurgitation (MR) in patients with chronic atrial fibrillation has not been thoroughly discussed. Although there is insufficient evidence to surgically treat atrial functional MR, it is considered to be reasonable for those patients with severe atrial functional MR who have symptoms of heart failure despite adequate medical therapy. Herein, we report a useful technique for mitral valve repair using posterior mitral leaflet (PML) augmentation with autologous pericardium to obtain good mitral valve coaptation and eliminate atrial functional MR, including tethered PML, in a nonelderly patient. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Author

Nouso, Kazuhiro, Amano, Maho, Ito, Yoichi M., Miyahara, Koji, Morimoto, Yuki, Kato, Hironari, Tsutsumi, Koichiro, Tomoda, Takeshi, Yamamoto, Naoki, Nakamura, Shinichiro, Kobayashi, Sayo, Kuwaki, Kenji, Hagihara, Hiroaki, Onishi, Hideki, Miyake, Yasuhiro, Ikeda, Fusao, Shiraha, Hidenori, Takaki, Akinobu, Nakahara, Taku, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2013
Full Text
View/download PDF

28. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

Author

Miyahara, Koji, Nouso, Kazuhiro, Morimoto, Yuki, Takeuchi, Yasuto, Hagihara, Hiroaki, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwadou, Shouta, Kobayashi, Yoshiyuki, Takaguchi, Koichi, Takuma, Yoshitaka, Takabatake, Hiroyuki, Sakaguchi, Kohsaku, and Yamamoto, Kazuhide

Published
2014
Full Text
View/download PDF

47. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis

Author

Nakamura Shinichiro, Takaki Akinobu, Hagihara Hiroaki, Toshimori Junichi, Ohnishi Hideki, Kuwaki Kenji, Uemura Masayuki, Takaoka Nobuyuki, Iwamuro Masaya, Horiguchi Shigeru, Matsubara Minoru, Tanaka Shigetomi, Nishina Shin-ichi, Shiraha Hidenori, Nakanishi Yutaka, Kobayashi Yoshiyuki, Nouso Kazuhiro, Yagi Takahito, and Yamamoto Kazuhide

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Runt-related transcription factor 3 (RUNX3) is known as a tumor suppressor gene for gastric cancer and other cancers, this gene may be involved in the development of hepatocellular carcinoma (HCC). Methods RUNX3 expression was analyzed by immunoblot and immunohistochemistry in HCC cells and tissues, respectively. Hep3B cells, lacking endogenous RUNX3, were introduced with RUNX3 constructs. Cell proliferation was measured using the MTT assay and apoptosis was evaluated using DAPI staining. Apoptosis signaling was assessed by immunoblot analysis. Results RUNX3 protein expression was frequently inactivated in the HCC cell lines (91%) and tissues (90%). RUNX3 expression inhibited 90 ± 8% of cell growth at 72 h in serum starved Hep3B cells. Forty-eight hour serum starvation-induced apoptosis and the percentage of apoptotic cells reached 31 ± 4% and 4 ± 1% in RUNX3-expressing Hep3B and control cells, respectively. Apoptotic activity was increased by Bim expression and caspase-3 and caspase-9 activation. Conclusion RUNX3 expression enhanced serum starvation-induced apoptosis in HCC cell lines. RUNX3 is deleted or weakly expressed in HCC, which leads to tumorigenesis by escaping apoptosis.

Published
2011
Full Text
View/download PDF

48. Heart transplantation in baboons using [alpha]1,3-galactosyltransferase gene-knockout pigs as donors: initial experience

Author

Kuwaki, Kenji, Tseng, Yau-Lin, Dor, Frank J M F, Shimizu, Akira, Houser, Stuart L, Sanderson, Todd M, Lancos, Courtney J, Prabharasuth, Derek D, Cheng, Jane, Moran, Kathleen, Hisashi, Yosuke, Mueller, Nicolas, Yamada, Kazuhiko, Greenstein, Julia L, Hawley, Robert J, Patience, Clive, Awwad, Michel, Fishman, Jay A, Robson, Simon C, Schuurman, Henk-Jan, Sachs, David H, and Cooper, David K C

Abstract

Author(s): Kenji Kuwaki [1]; Yau-Lin Tseng [1]; Frank J M F Dor [1]; Akira Shimizu [2]; Stuart L Houser [3]; Todd M Sanderson [1, 2]; Courtney J Lancos [1]; Derek [...]

Published
2005
Full Text
View/download PDF

49. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma.

Author

Oyama, Atsushi, Nouso, Kazuhiro, Yoshimura, Kenichi, Morimoto, Yuki, Nakamura, Shinichiro, Onishi, Hideki, Takaki, Akinobu, Iwadou, Shouta, Kariyama, Kazuya, Kuwaki, Kenji, Yabushita, Kazuhisa, Sakaguchi, Kosaku, Toshimori, Jyunichi, Kobashi, Haruhiko, Moriya, Akio, Ando, Masaharu, and Okada, Hiroyuki

Subjects
CHEMOEMBOLIZATION, CATHETER ablation, HEPATOCELLULAR carcinoma, CISPLATIN, SURVIVAL rate, CANCER chemotherapy
Abstract

Aim: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin is beneficial to patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. This study aimed to examine the effect of HAIC with cisplatin before radiofrequency ablation (RFA) in patients with HCC. Methods: This was a multicenter, single‐blinded, randomized controlled study (UMIN000007267). Early‐stage HCC patients were randomly assigned (1:1) to receive HAIC with cisplatin before RFA therapy (HAIC group) or RFA monotherapy (non‐HAIC group). The primary end‐point was recurrence‐free survival. Efficacy analysis and safety analysis followed the intention‐to‐treat principle. Results: Between August 2012 and July 2016, 74 patients were recruited. A total of 70 eligible patients were randomly assigned to the HAIC group (n = 35) and non‐HAIC group (n = 35). Recurrence‐free survival rates at 1 (3) year in the HAIC group and non‐HAIC group were 82.9% (54.3%) and 74.3% (34.3%), respectively (hazard ratio [HR], 0.597; 95% confidence interval [CI], 0.320–1.091; p = 0.094]. Subgroup analysis showed that the beneficial effect of HAIC was observed in patients with a single nodule and Child–Pugh score 5. Intrahepatic distant recurrence‐free survival rate in the HAIC group was significantly better than that in the non‐HAIC group (HR, 0.468; 95% CI, 0.235–0.896; p = 0.022). Adverse events were observed in just two patients in the HAIC group (6%) – grade 2 cholecystitis and grade 2 hyperkalemia. Conclusions: HAIC with cisplatin before RFA did not significantly decrease recurrence in patients with early‐stage HCC. However, it might be effective in preventing intrahepatic distant recurrence. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results